Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
FDA Approves BiTE Therapy for Adults and Children with Leukemia Subtype
Blinatumomab has received full approval from the FDA after long-term data confirmed its safety and efficacy.
News
37 Patient Organizations Applaud Proposed Rule to Rein in Short-Term Health Plans
Short-term health plans don’t offer typical health insurance benefits and don’t include consumer protections such as coverage for pre-existing conditi…
Research
Apply to the Career Development Program (CDP)
Supporting talented young early-career physicians and scientists. Go directly to the information page on the CDP application process or browse our…
Research
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, in Preclinical Leukemia Models at the European Hematology Association Congress
WATERTOWN, Mass., June 09, 2023 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degr…
Patient Education Webcasts
Spotlight on Aggressive Non-Hodgkin Lymphomas (NHL)
Research
Immune-Onc Therapeutics Announces IO-202 Granted Fast Track Designation by FDA for the Treatment of Relapsed or Refractory CMML
PALO ALTO, Calif., June 7, 2023 – Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage oncology company dedicated to the discovery …
News
Subaru Partners with The Leukemia & Lymphoma Society for 8th Year to Share Warmth, Love and Relief with Patients Facing Cancer
Subaru of America, Inc. is renewing its partnership with The Leukemia & Lymphoma Society (LLS) during Subaru Loves to Care® month in June. Subaru will…
News
FDA Approves New Bispecific Antibody for Non-Hodgkin Lymphoma Subtype
Epcoritamab gives patients with diffuse large B-cell lymphoma another treatment option.
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
